Reaxys accesses MilliporeSigma’s vast chemistry portfolio for seamless customer experience

New collaboration enables users to purchase chemicals and compounds directly from MilliporeSigma

New York, June 26, 2017

Elsevier, the information analytics company specializing in science and health, today announced a new partnership with MilliporeSigma, the life science business of Merck KGaA, Darmstadt, Germany, to integrate its chemical products into Reaxys, Elsevier’s premier chemistry database. Users of Reaxys will be able to access an additional 43,000 MilliporeSigma compounds and chemicals, with data provided directly from the company. The collaboration also means that users will have access to both product availability as well as standard MilliporeSigma pricing for U.S.-based customers.

The integration with MilliporeSigma provides Reaxys users working in pharmaceutical drug discovery, chemical R&D and more, with a number of key benefits including a more efficient, time-saving process which enables users to purchase chemicals and compounds directly from MilliporeSigma. High-quality and reliable data provided by MilliporeSigma, in combination with Reaxys’ unparalleled published experimental reaction data, gives users confidence in making right decisions in their research process. Further, the integration means users are able to quickly compare the cost of purchasing a compound against making it internally. This allows a better allocation of budget resources, while also saving Reaxys’ users’ time, and accelerating their research.

“We are continually looking for ways to develop the functionality of Reaxys for our users’ needs, in order to help support and accelerate their research,” commented Christian Boehm, Director of Chemistry Solutions at Elsevier. “MilliporeSigma is recognized as an industry leader, and so this collaboration is a great addition to Reaxys, which will prove beneficial to users.”

Reaxys contains more than 240 years of unparalleled chemistry content, including 105 million organic, inorganic and organometallic compounds, 42 million chemical reactions, 500 million published experimental facts, 16,000 chemistry related periodicals and six indexing sources for a cross-disciplinary view of chemistry.


About the Life Science Business of Merck KGaA, Darmstadt, Germany
The life science business of Merck KGaA, Darmstadt, Germany, which operates as MilliporeSigma in the U.S. and Canada, has 19,000 employees and 65 manufacturing sites worldwide, with a portfolio of more than 300,000 products enabling scientific discovery. Udit Batra is the global chief executive officer of MilliporeSigma.

Merck KGaA, Darmstadt, Germany completed its $17 billion acquisition of Sigma-Aldrich in November 2015, creating a leader in the $125 billion global life science industry.

Merck KGaA, Darmstadt, Germany is a leading company for innovative and top-quality high-tech products in healthcare, life science and performance materials. The company has six businesses – Biopharmaceuticals, Consumer Health, Allergopharma, Biosimilars, Life Science and Performance Materials – and generated sales of €15 billion in 2016. Around 50,000 employees work in 66 countries to improve the quality of life for patients, to foster the success of customers and to help meet global challenges.

Merck KGaA, Darmstadt, Germany is the world’s oldest pharmaceutical and chemical company – since 1668, the company has stood for innovation, business success and responsible entrepreneurship. Holding an approximately 70 percent interest, the founding family remains the majority owner of the company to this day. The company holds the global rights to the name and the trademark “Merck” internationally except for the United States and Canada, where the company operates as EMD Serono, MilliporeSigma and EMD Performance Materials.

About Elsevier
Elsevier is a global information analytics business that helps scientists and clinicians to find new answers, reshape human knowledge, and tackle the most urgent human crises. For 140 years, we have partnered with the research world to curate and verify scientific knowledge. Today, we’re committed to bringing that rigor to a new generation of platforms. Elsevier provides digital solutions and tools in the areas of strategic research management, R&D performance, clinical decision support, and professional education; including ScienceDirect, Scopus, SciVal, ClinicalKey and Sherpath. Elsevier publishes over 2,500 digitized journals, including The Lancet and Cell, 39,000 e-book titles and many iconic reference works, including Gray's Anatomy. Elsevier is part of RELX, a global provider of information-based analytics and decision tools for professional and business customers.

Media Contact
Christopher Capot
Global Communications, Elsevier
+1 917 704 5174